跳至主要内容
临床试验/NL-OMON47003
NL-OMON47003
已完成
不适用

Synovial Tissue characteristics in Rheumatoid Arthritis patients TreAted with their FIrst Tnf-inhibitor - STRATAFIT

niversitair Medisch Centrum Utrecht0 个研究点目标入组 50 人待定

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
未指定
发起方
niversitair Medisch Centrum Utrecht
入组人数
50
状态
已完成
最后更新
2年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
2年前
研究类型
Observational invasive

研究者

发起方
niversitair Medisch Centrum Utrecht

入排标准

入选标准

  • \* Age \* 18 years
  • \* Fulfilling 2010 American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) classification criteria for RA (Appendix A).
  • \* DAS28 \* 3\.2
  • \* At least one clinically active wrist or knee or MCP joint
  • \* Start with aTNFi (all currently approved TNFi are allowed\* infliximab (3 mg/kg at week 0, 2, 6 and 14\), etanercept, adalimumab, golimumab, certolizumab pegol) within 4 weeks from the baseline study visit.
  • \* Having insufficient response to treatment with \* 2 conventional DMARDs.
  • \* Current treatment with either methotrexate (\*10 mg/week), sulfasalazine (\*2000 mg/day), hydroxychloroquine (\*200 mg/day), and/or leflunomide (\*10 mg/day).
  • \* Naïve to previous biological treatment regimens, including other TNFi, rituximab, abatacept, tocilizumab (and biosimilar equivalents).

排除标准

  • \* Treatment with systemic glucocorticoids at a dose above 10 mg/day of prednisone or equivalent within 4 weeks of enrolment.
  • \* Treatment with intra\-articular glucocorticoids in a knee or wrist or MCP joint within 3 months of enrolment.
  • \* Any rheumatic disease other than RA (except secondary Sjogren\*s syndrome)

结局指标

主要结局

未指定

相似试验